Target intelligence / Profile preview

Beta-tubulin (taxane binding site) (TUBB)

Target
TUBB
Molecular classification
Cytoskeletal protein, Structural protein, GTPase
01

Overview

Beta-tubulin is a fundamental structural protein that, along with alpha-tubulin, forms heterodimers which polymerize into microtubules [3, 13, 18]. These microtubules are dynamic filaments essential for maintaining cell shape, enabling intracellular transport, and forming the mitotic spindle during cell division [3, 12, 13, 18]. The taxane binding site is a specific pocket located on the luminal surface of the beta-tubulin subunit within the microtubule polymer [8, 10, 14, 18]. Drugs targeting this site, such as paclitaxel and docetaxel, act as microtubule-stabilizing agents by binding to and stabilizing the lattice, which prevents the dynamic depolymerization necessary for chromosome segregation [3, 8, 9, 14, 18]. This interference leads to mitotic arrest at the G2/M phase and triggers apoptosis, making the taxane site a critical target in the treatment of numerous solid tumors, including breast, lung, and ovarian cancers [1, 3, 14]. However, therapeutic efficacy is often limited by the development of resistance—frequently through mutations in the binding site or the upregulation of specific tubulin isotypes like TUBB3—and by systemic toxicities such as peripheral neuropathy and neutropenia [6, 11, 14, 15, 18].

Other names
Taxane binding siteTaxoid sitePaclitaxel binding siteMicrotubule-stabilizing agent site
02

Mechanism of action

Binds to the taxane site on the luminal surface of beta-tubulin within microtubules, stabilizing the polymer and inhibiting depolymerization [3, 8, 14]. This disrupts mitotic spindle dynamics, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis [9, 11, 18].

03

Biological functions

Cell divisionMitosisIntracellular transportCell motilityStructural integrity
04

Disease associations

CancerBreast cancerOvarian cancerLung cancerProstate cancerKaposi's sarcoma
05

Safety considerations

Peripheral neuropathy [6, 14, 18]Myelosuppression [6, 11, 14]Neutropenia [6, 11, 14]Hypersensitivity reactions [11, 14]Alopecia [18]Drug resistance [1, 10, 15]
06

Interacting drugs

Paclitaxel

5 more in the full profile.

07

Biomarkers

TUBB3 (Beta-III tubulin) expression [1, 4, 5]Tau protein expression [2]MAP4 expression [3]Stathmin expression [1]

Beyond the preview

Go deeper on Beta-tubulin (taxane binding site) (TUBB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-tubulin (taxane binding site) (TUBB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call